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Abstract:
The developments in biotechnology have brought not only benets but also harms to society. On the one
hand, the biotechnologically modied products has rapidly changed our lifestyle, but on the other hand, they
could also endanger the ecosystem due to their reproduction and novel characteristics, and raise sharp debate
over social values, including moral and religious values, and ethical standards. These rapid developments
and problems of biotechnology posed a signicant challenge to policymakers. E.g., are current regulations
enough? Or do we need more regulations for biotechnological experiments and the development of genetically
modied products because of their potential negative impacts? After comparing the advantages (such as
the avoidance of the negative and special inuences of biotechnology, and the solution of market failure
and social injustice) and disadvantages (such as economic loss, government failure, and violation of social
justice and freedom of scientic experiments), this research addressed that more and specied regulations
are necessary. However, the scope of regulations { or how much control the government should have in
scientic development { should be reasonably limited to give consideration to the independence of scientic
elds, and economic developments. First, the regulations of biotechnological experiments should be looser
than those of genetically modied products because of the dierent substantial impacts on consumers, and
the respect of the freedom of speech (or research). Second, more participation of the general public will help
to avoid the professionals' and governments' arbitrary decisions. Third, the regulations of \Physical Risks"
and \Social Risks and Ethical Considerations" should be dierent because their inuences are varied.
Key Words: Biotechnology, Biotechnological Research, Biotechnologically (geneti-
cally) Modied Product, Regulation.
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41. Issue
The 21 century's developments in biotechnology have brought not only benets but also harms to society.
On the one hand, biotechnology has rapidly changed agricultural and medical practices, promising new drug,
cloned animals, and biological products, that have altered ou lifestyle. For example, about 30 to 35 percent
of soybeans and 25 percent of corn grown in United States in 1998 came from genetically modied seeds1.
Approximately 60 percent of packaged foods in supermarkets contain genetically modied organisms2.
Despite its benets, all the changes have not been benecial. First, genetically modied products could
endanger the ecosystem due to their reproduction and novel characteristics. Though there is no signicant
evidence, scientists are exploring the possibility that genetically modied products could change some func-
tions of biological system as a result of genetic modication and inserted foreign genes. Second, genetically
modied products and biotechnological experiments have raised sharp debate over social values, including
moral and religious values, and ethical standards. Society is divided on the issue because biotechnology is
strongly related to human's basic relief and value system.
The rapid developments of biotechnology in the last 20 years posed a signicant challenge to policymakers.
In order to assess and control the new developments of biotechnology and the accompanying ethical ques-
tions, environmental concerns, and potential physical damages, regulations are necessary. The regulations
can be divided into two main categories. One is \biotechnological experiments" that are related to research
and development (R&D) processes in manufacturing. The other is category genetically modied products
(GM products) that may be directly used or ingested by consumers.
However, the scope of regulations { or how much control the government should have in scientic development
{ is a hotly debated issue. Are current regulations (see discussion infra part 3) enough? Or do we need
more regulations for biotechnological experiments and the development of genetically modied products
because of their potential negative impacts on biological and ecological system, or simply because of their
dierent and special characteristics. These concerns arose in the 1980s and have been debated in political,
scientic, and ethical areas. For example, the debate on how much the government should regulate biological
experiments has focused on moral values and economic development and the debate continues raging (see
discussion infra part 4.1, 4.2 and 5.2). Governments, the public, and scientists also have argued about
whether the risks of genetically modied products include social risks and physical risks (see discussion
infra part 6.3). These conicts are mainly between scientists, governments, manufacturers, and the public.
Scientists and manufacturers generally argue that existing laws that regulate traditional technology and
its derivative products are satisfactory for biotechnological experiments and genetically modied products.
They believe that (1) too much regulation would cause biotechnology industry's dilemma and stymie its
development3, and (2) the government should not intervene too much in business and scientic aairs and
the market. However, the government and some conservatives have argued that new and more extensive
regulations are necessary4 because (1) the inuences of genetically modied products are new and unknown
in some cases, and totally dierent from those of traditional technological products, and (2) existing laws
do not address biotechnological issues. For example, the Federal Food, Drug, and Cosmetic Act and related
1Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
L. J. 649,649 (2000).
2Id.
3U.K. to Overhaul Biotechnology Regulations, 5 No. 12 J. Proprietary Rts. 40, 40 (1993).
4Teresa Pechulis Buono, Biotechnology-Derived Pharmaceuticals : Harmonizing Regional Regulations, 18 Suolk
Transnat'l L. Rev. 133, 138 (1995).
5evaluation system are designed to regulate technological end products. Few existing standards and acts
regulate scientic research5.
Therefore, this article will rst discuss the characteristics and special inuences of biotechnological experi-
ments and genetically modied products (see discussion infra part 2.3). And then it will address the cons
and pros of more regulations in biotechnology (see discussion infra parts 4 and 5). Last, this article will
discuss the substantial content of the regulations, such as who will regulate and what biotechnological issues
should be regulated (see discussion infra part 6), and conclude that more regulations is necessary because
of the protection of consumers and moral values, but the scope of regulations should be limited to give
consideration to the independence of scientic elds, economic developments.
2. Introduction to Biotechnology
2.1. The development of Biotechnology
The term biotechnology describes a laboratory technique that uses biological organisms to create new modi-
ed organic products6. In fact, biotechnology is not a totally new and developing sciences as some biotechno-
logical applications such as plant hybridization have existed for centuries. Thousands years ago, people had
started to use breeding methods to improve the quality and quantity of crops and farm animals by hybridiz-
ing dierent breeds. For example, the mule is the hybrid from a donkey and a horse. Our ancestors also used
microorganisms to make bread, to convert milk into cheese, and to brew alcoholic beverages7. Centuries ago,
these traditional biotechnological applications were limited to a small number of elds because people had
no knowledge about molecular biology and biological mechanisms of the body, in part due to technology {
they had no access to microscopes and other tools to examine the molecular structure of cells.
The biotechnology eld rapidly advanced in 1953 when basic double-helix structure of heredity substance,
deoxyribonucleic acid (DNA) was discovered and described by James Watson and Francis Crick8. This
discovery helped scientists understanding the inherent heredity mechanism, deciphering the genetic code,
which led to the biotechnological techniques revolution. Through the understanding of genes, scientists
could manipulate genetic material and change the structure on the smallest known scale { individual genes
{ by applying the techniques of genetic engineering. The use of genetic modication allows scientists to
bypass traditional sex-crossing and natural selection in breeding processes, and makes it possible to eliminate
undesired traits or add desired traits to a plant or animal9. Therefore, the \improvement" of the genetically
modied animals and plants is no more random and natural but controlled by human hands. Today, scientists
are no longer `passive observers' of life, but `active creators' of life10. For example, if scientists want to create
a new and sweeter species of tomato, and they know that the sweetness is controlled by DNA-X, they can
5Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 183 (1987).
6Teresa Pechulis Buono, Biotechnology-Derived Pharmaceuticals : Harmonizing Regional Regulations, 18 Suolk
Transnat'l L. Rev. 133, 136 (1995).
7Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 967 (2d ed. 1991).
8Id, 964.
9Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
L. J. 649,652 (2000).
10Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 184 (1987).
6use a restriction enzyme to cut out the DNA molecule in the host's (origin tomato's) microorganism and
replace or insert foreign \sweet" DNA to produce an \improvement" or \genetic modied" tomato (novel
tomato or genetically modied tomato) which has never existed before in nature. Another example of genetic
modication is that the gene producing insulin in a human cell can be isolated and inserted into a bacterium
that can produce or clone many identical copies of the gene. If the gene can be coaxed to manufacture the
same insulin in bacteria that it does in a human, large amounts of low-cost insulin can be produced to aid
diabetics11.
With advanced techniques, the application of biotechnology has become varied and widespread in many
industries such as agriculture, medicine, pharmaceuticals and the environment. It also has improved human
life in many areas particularly with new biotechnology-derived pharmaceuticals for treating diseases, and
with genetically modied agricultural products that increase the production quantity of crops. In medicine,
genetic research has produced many medical benets because genes play a key role in the disease process and
treatments12. Scientists have also developed numerous genetically modied crops that are more resistant
extreme weather, salty soil, insects and animals than the original species, and produce more eciently.
However, like many other powerful new technologies, biotechnology carries risks as well as benets13. These
inuences include not only the visible eects such as physical harm to people and animals and environmental
pollutions, but also the invisible eects such as emotional reactions, destruction of established social values
and ethical concerns.
2.2. The Denition of Biotechnology
Biotechnology, dened as technology that transform biological processes, includes a board range applications
including traditional applications that can create genetically modied products. The inuences of traditional
biotechnology is not absolutely immediate and danger. For example, it is hard to imagine the fermented bread
would cause physical injuries. In narrowest denition, biotechnology employs recently established biological
technologies using living organisms14 (or parts of organisms) and techniques such as cell fusion, recombinant
DNA, and bioprocessing15 to make or modify products, or to alter plants or animals biologically for benecial
use. Comparatively, those newly developed biotechnologies strongly involve product development in elds
such as agriculture, environmental monitoring, and health care16, and have great possibilities to cause
physical harms and environmental pollutions.
There are two reasons for using the narrow denition in this article. First, the regulatory approach was
developed to deal with the problems following with the development of modern biotechnology. Therefore,
the traditional biotechnology which spans hundreds years and has no signicant harm does not need more
regulating. Second, the narrow denition that excludes the application of traditional biotechnology would
help to simplify this issue.
2.3. The Characteristics of Biotechnology
11Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 967 (2d ed. 1991).
12Henry T. Greely, Speech : The Revolution in Human Genetics: Implications for Human Societies, 52 S.C.L. Rev.
377, 377 (2001).
13Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 964 (2d ed. 1991).
14Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 185 (1987).
15Teresa Pechulis Buono, Biotechnology-Derived Pharmaceuticals: Harmonizing Regional Regulations, 18 Suolk
Transnat'l L. Rev. 133, 136 (1995).
16Id, 136-37.
7Because biotechnology is a technique designed to biotechnologically modify products by using living biological
organisms and aimed at improving the functions of plants or animals, the relationship between biotechnology
and life is close. In addition, because biotechnology deals with the issues related to life, there are some special
characteristics that set biotechnology apart from other technologies.
(1) Biotechnology as it relates to humanity
There is an unavoidable contradiction between nature and articiality existing in the develop-
ment of technology. Namely, because biotechnologically modied products are articial products
manufactured by scientists' hands but not by Mother Nature, there are numerous arguments about
how much should scientists intervene the naturally biological processes. On the one hand, some
experts argued technology should obey the natural laws because it existed and developed under the
natural environment. On the other hand, because technology is a tool used to change natural phe-
nomena to meet human needs, it is unavoidable to step in the naturally biological processes. Thus,
the contradictions raised by biotechnology are that scientists want to change natural phenomena
via biotechnology, including humans, animals and plants. The natural development, growth, exis-
tence, and reproduction of human or other living organisms are strongly intervened and molecularly
modied by biotechnology and as results, become unnatural and articial. Because biotechnology
involves manipulation of nature, it implies high relevance with of humanity and nature.
(2) Biotechnology is related not only to lifestyle but also to life itself
Unlike other traditional technologies that aim to control, manipulate, and improve the physical
environment, such as chemical or civil engineering, biotechnology aims to change human, animal
and plant's biological structures. Biotechnology is not focused on external and temporal change by
inventing new equipments, but is interested in changing vital life processes by internal and long-term
intervention.
(3) Biotechnology is related to society values
No other technology more directly related to family, social and religious values than biotech-
nology. Because biotechnology deals directly with and tries to change life processes and life itself,
biotechnology and threatens basic beliefs, and social and religious values. And because biotechnology
has a close relationship, like the issue of abortion, there are highly conicting and entirely dierent
attitudes and opinions toward biotechnology. Achieving a common consensus is dicult because the
conicts involves with the most basic ideas of human's values, and raises ethical questions such as
should human manipulate natural biological processes? Should we clone animals, or people?
3. Regulatory Approach to Biotechnology in U.S. and Its Shortfalls
Based on its various purposes, characteristics and operations, the regulatory approach of biotechnology can
be divided into two main elds in U.S. One is regulating \biotechnology research and development" which
focuses on the pure scientic research and biotechnological experiments in science society and manufacturers
before manufacturing. The other is regulating \genetically modied products" which focuses on inuences
of the nal products on consumers, ecology system, and environment.
83.1. Biotechnology Research and Development
The regulatory history of biotechnology experiments in the United States began in 1970s when a small
group of scientists promoted the needs of regulation17. In 1976, the U.S. National Institutes of Health (NIH)
established restrictive guidelines for the use of recombinant DNA technology18. The guidelines oered rec-
ommendations for protecting the public and the environment from risks associated with federally funded
recombinant DNA research19.
The guidelines though were limited as they applied only to public funded research. Private funded research
was not regulated. President Ronald Reagan in 1984 formed a comprehensive regulatory program, the
\Coordinated Framework for Regulation of Biotechnology" (\Coordinated Framework"), to regulate both
private and public funded research; it was revised in 198620. The Coordinated Framework involves four
federal administrative agencies: the Environmental Protection Agency (EPA), the Occupational Safety and
Health Administration (OSHA), the Department of Agriculture (DOA), and the Food and Drug Adminis-
tration (FDA). Under existing law, each agency is responsible for establishing and updating a biotechnology
regulatory structure pertaining to its regulatory activities21.
Besides the division of responsibilities and powers, the range of regulations also became broader then the
initial one. The early controls were exercised only over recombinant deoxyribonucleic acid (rDNA), but cur-
rent controls cover other methods of biotechnology such as recombinant ribonucleic acid (rRNA) technology
and cell fusion22.
However, some experts have argued that the existing laws are not adequate to regulate biological experi-
ments. First, the Coordinated Framework is only a framework or a division of labor. It can help to clarify
dierent agencies' responsibilities and powers regarding new developments in biotechnology. But because
the framework based in existing laws, which were designed for regulating the post-evaluation and derived
products but not designed for regulating research and development before production, this framework does
not resolve the debate on how and how much the government should interfere with scientic aairs. For
example, biotechnological experiments are not clearly in the Federal Food, Drug, and Cosmetic Act. Because
of the absence, the government has no adequate means to regulate manufacturers' development or research
on genetically modied products, and manufacturers have no trustworthy standards to follow.
Second, even though there are some clauses related to regulations of scientic researches, the existing laws
were designed to regulate traditional technology. The federal legislature in making regulations did not
consider the special characteristics of biotechnology, such as reproduction process and long-term eects.
Those regulatory strategies obviously cannot handle the potentially new and signicant problems caused by
biotechnology. Therefore, it is also improper to apply or extend existing laws to regulate biotechnology.
3.2. Genetically Modied Products
17Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 189 (1987)
18Teresa Pechulis Buono, Biotechnology-Derived Pharmaceuticals : Harmonizing Regional Regulations, 18 Suolk
Transnat'l L. Rev. 133, 139 (1995).
19Id, 140.
20Id.
Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl. L.
183, 183 (1987).
21Peter Mostow, Reassessing the Scope of Federal Biotechnology Oversight, 10 Pace Envtl. L. Rev. 227, 233 (1992).
22Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 185 (1987).
9Like biotechnology experiments, U.S. federal government has similar policies toward genetically modied
products. Until now, no statutory provisions or regulations address biotechnology specically23. Federal
policies, such as the Federal Food, Drug, and Cosmetic Act, backed by the biological research community
and manufacturers states that genetically modied products are to be treated similarly to other potentially
hazardous and harmful products, such as new drugs and food, with the exception that genetic modied
products and genetic engineering techniques are also subject to risk assessment and evaluation under the
FDA's prior review requirement24. For example, except for marking products with \genetically modied
products" or similar statements on the labels, the regulations of genetically modied products are basically
the same as other food, drugs, medical devices, cosmetics, and animal food and drugs under the Federal
Food, Drug, and Cosmetic Act.
According to Professor Peter Barton Hutt, two existing types of general federal regulatory statutes protect
the public's health and safety: those that regulate particular products, and those that regulate industrial
processes25.
(1) Particular Products: According to the Toxic Substances Control Act (TSCA) of 1976, the
EPA can set \requirements or limitations upon manufacturer or use that may be justied to prevent
an unreasonable risk to health or environment" 26, and the range covers both old and new chemicals,
including biotechnology products. The Organic Act of 1944, the Federal Plant Pest Act, Noxious Weed
Act, and Federal Seed Act also authorized the USDA plenary authority to regulate the development
and introduction of new plants and plant pests. The Endangered Species Act of 1973 authorized De-
partment of the Interior (DOI) to regulate \the importation and introduction of exotic species of plants
or animals into natural ecosystems in United States."27 Food, drugs, medical devices, and cosmetics
are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act of 1938. Human biological
drugs are regulated under the Biologics Act of 1902, and animal biological drugs are regulated under
the Virus Serum Toxin Act of 1913.
(2) Industrial Processes: The Occupational Safety and Health Act required employers to maintain
working conditions to protect employees from harm, and authorizes OSHA to issue related standards.
In addition, several environmental statutes, such as the Clean Air Act, Water Pollution Control Act,
Safe Water Drinking Act, Resource Conservation and Recovery Act, Comprehensive Environmental
Response, Compensation, and Liability Act, and the Marine Protection, Research, and Sanctuaries
Act are available to \regulate the byproducts of industrial processes in order to assure a healthy and
unpolluted environment."28 Besides, obtaining pre-market approvals, bioengineered products' manu-
facturers need to apply for a new drug application (NDA), a biological product license, new animal
drug application (NADA), and a new medical devices application to protect the public's health29. For
food products, the preclearance or approval of food additives including those prepared using biotech-
nology techniques is required30, and some standards have been put into place over the past decade. For
example, manufacturers of new drugs and biologics must operate in conformance or compliance with
current good manufacturing practice (CGMP) regulations.31
23Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 976 (2d ed. 1991).
24Amal Kawar, Richard Sherlock, Theoretical Issues in the Regulation of Genetically Engineered Organisms: The
Case of Deliberate Release, 7 (2) Politics and The Life Science 129, 129 (1989).
25Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 973 (2d ed. 1991).
10Although no specic statute regulates genetically modied products, some experts argue that
the existing statutory system is adequate for the regulation of genetically modied products because
the agencies can \extend their experience with these regulatory mechanisms and apply them to the
products of biotechnological process."32 The FDA also proposes no new procedures and requirements
for individuals or industries to regulate the genetically modied products.33 Currently, all regulations
governing biotechnologically modied products are controlled by various federal agencies, including the
FDA, OSHA, DOA, and EPA. This diversied and unorganized system can cause ineciency, especially
when the inuences of genetically modied products are multidimensional and can negatively aect
the health and safety of living beings and the environment. In addition, if we still apply the existing
old regulatory strategies to regulate the new genetically modied product, we might ignore the special
eects of genetically modied products on public health, environmental protection, the ecosystem's
balance, and social orders, such as moral and religious values Even though the U.S. Congress gave
the FDA authority to regulate products regardless of how they are manufactured, under the Federal
Food, Drug, and Cosmetic Act, and the Public Health Services Act, it is doubtful whether the FDA
can eectively regulate genetically modied products if there is no universal and detailed regulation to
address the complex dimensions and problems of the products.
While some politicians, business groups, scholars, scientists and policymakers believe that the current statu-
tory provisions can be extended to t the regulations of genetically modied products, I question this premise:
(1)
Biotechnology is a virtually new and rapidly developing technology with very little evidence on
the eects of genetic medications of plant and animal organisms for experts to evaluate. Furthermore,
some believe that the eects of some biogenetic processes (i.e., those that aect the environment or
reproductive processes) will not be evident for years or decades to come.
(2) Current statutory provisions are not designed for genetically modied products. The current
statutes might not \t" genetically modied products, and might neglect some important outcomes or
problems. For example, there is no particular statutory provision that deals with food produced by new
biotechnology.34 Most issues concerning the safety of food will involve the application of either section
342(a)(1) or section 349 of Federal Food, Drug, and Cosmetic Act. According section 342(a)(1),35 \if
a food produced by new biotechnology contains a higher level of a substance than it might ordinarily
have", the food may be \injurious to health" under section 342(a)(1). But should the inserted genes be
counted as a level of a substance"? If the eects of genetically modied products occur over a long period
of time, say 100 years, or four generations, through complex mechanisms, could the current regulations
eectively address the possibly negative outcomes? We will discuss these questions in infra parts 4.1.2
and 4.1.3.
Since 1978, FDA has tried to propose regulations requiring that all recombinant research on, and production
of, any product for which a submission was to be made to FDA must conducted in compliance with signicant
guidelines36, such as NIH Guidelines37, \points to consider38" and general requirements for manufacturing
36Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 976 (2d ed. 1991).
3743 Fed. Reg. 60134 (December 22, 1978).
3849 Fed. Reg. 1138 (January 9, 1984), 49 Fed. Reg. 23456 (June 6, 1984), 53 Fed. Reg. 5468 (February 24, 1984),
and 54 Fed. Reg. 46305 (November 2, 1989).
11biotechnological products39. Government also tried to coordinate all federal regulatory agencies to contem-
plate and manage overall regulations of biotechnology. For example, in 1984, Interagency Working Group
on Biotechnology, chaired by the Oce of Science and Technology Policy (OSTP), concluded that \a closely
managed regulation of biotechnology by all federal regulatory agencies under OSTP oversight40." But this
suggestion was abandoned by White House because of fearing \adding another layer regulation and hinder
commercialization of biotechnology41." But these endeavors still cannot resolve all of the problems which are
caused by biotechnology because of political interference, interest conicts and lack of a macrocosm design.
4. The Benets of Increasing Regulations on Biotechnology
4.1. The Impacts of Biotechnology
The need for more regulations on biotechnology stems mainly from the dierences between biotechnology
and traditional technology. In this section, I discuss three key characteristics of biotechnology and genetically
modied products, and explain why these characteristics necessitate more regulations.
4.1.1. Biotechnology and Social Values
Because biotechnology has a close relationship with social values, the impacts of biotechnology developments
result not only in physical risks such as health problems, environmental pollution and ecosystem violations,
but they also pose a social risk as they call into question social values and challenge society's moral and
religious values. However, regulatory agencies generally are concerned with physical risks, but neglect the
social impact on society. For example, the federal agencies have complete assess systems to evaluate human
physical harms, and environmental pollutions, but do not have proper assess systems to evaluate the inu-
ences on moral and religious values, and people's spiritual functions.
In many cases, conservatives and religious groups are the main proponents of to greater regulations, along
with the biotechnology industry which is focused on protecting its interests. These social and moral issues
are deeply based in cultural and religious beliefs and values and consequently, it may take decades, or cen-
turies for societies to form a consensus on these issues. And the support reects the burden of the freedom
of biotechnological research is mainly from traditional social morality and religious values. For instance, the
issue of cloning and using fetus tissue to generate new organs are two controversial issues. The opponents
argued the biotechnology option should force society as a whole to reexamine moral values regarding who
should control life and what is life? Should we use one human's genetic material to form the organs of
another's? Should the donors be compensated? Can fetuses be bought and sold?
The most controversial issue is embryo experiments and related products because they directly call into
question human dignity, moral frameworks, and religious faith. We can use this example to describe the
relationship between biotechnology and values. First, since their is no consensus about whether the em-
bryo is a human being or not, the utilization of embryos in basic research and in medical applications have
prompted religious, political and other interested groups to advocate the protection of human dignity, which
in most cases means, a call to ban the use of embryos in research and in medical applications. Second, many
religious groups deeply believe that humans should not play the \Creator's role." However, advocates of the
use of embryos argue that they are not playing \God" but are trying to improve the quality of human's life,
cure diseases and prolong life.. Thus, as we can see, biotechnology creates many conicts. Some may argue
3943 Fed. Reg. 27622 (December 6, 1984), and 51 Fed. Reg. 44451 (December 10, 1986).
40Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 976 (2d ed. 1991).
41Id.
12that these conicts are good for a society to debate and engage in and others may argue that these conicts
are inevitable and must be addressed sooner or later because biotechnology and science can not be readily
controlled.
Even though some biotechnological techniques and genetically modied products do not directly aect core
moral and religious values, such as genetically modied plants and microorganisms because they are not
related to human dignity. Many skeptics still argue that these products go against natural order and could
irreparably damage the environment, and in this way, would violate human dignity, and moral and religious
values.
These social and moral debates might be very slight in other traditional technologies. But because of the close
relationship between biotechnology and moral values, biotechnology could escalate into huge conicts and
possibly economic losses or illegal operations if the government ignores these issues. Therefore, even though
biotechnology is one branch of technology, and biotechnology scientists and manufacturers have professional
standards, and even though religious and moral groups have valid points, it seems that society will need
to set forth regulations for biotechnology and in so doing, must consider social, cultural, religious and
moral values along with the economic, scientic and medical benets that biotechnology oers. Because the
traditional technologies do not produce life-altering results and thus such strong conicts, current regulations
need to be updated and reinforced to address biotechnology issues. Therefore, biotechnological science and
manufacturers of genetically modied products need specic regulations that address these moral issues. It
seems that we need not only regulations specic to biotechnology research and the manufacture of genetically
modied products but we need regulations that take into consideration the impacts on entire society including
values shifts. Only then , can biotechnology set clear goals, function freely and achieve its goals.
4.1.2. The Uncertain Inuences of Biotechnology
The techniques of biotechnology are \extremely powerful because they allow a large number of controls
over biological systems." 42 The enormous power of biotechnology over biological and ecological systems
can result in strong and unexpected inuences that are far more powerful than the eects of traditional
technologies. This also supports the need for new or updated regulations of biotechnological experiments
and genetically modied products. The fact that negative results of genetically modied products could
surface decades, even centuries later strengthens the argument in favor of a cautious approach to managing
biotechnology. Three factors cause this uncertainty:
(a) Modern biotechnology is a relatively new and developing science, less than 50 years old if we
consider Watson and Crick's \discovery" of the basic double-helix structure of DNA in 1953. Because
of this limited time and experience, scientists, manufacturers and other interested parties have not been
able to accumulate enough information to accurately evaluate the outcomes.
42Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 964 (2d ed. 1991).
13Due to the rapid development of biotechnology and the potential enormity of its eects on biological
and ecological systems, not enough tine has passed to properly assess the results, and to envision and
measure the possible consequences accompanying these developments. And the insucient time in order
to collect information on biotechnology developments could cause not only unpredictable outcomes but
also diculties in building causation relationship. It becomes dicult to identify the long term harm, if
any, connected to biotechnology techniques.43 For example, the scientists can use genetically modied
microorganisms to produce more and purer proteins to supply the market. But scientists cannot ade-
quately assess whether these modied microorganisms could, over time, develop new characteristics or
if the newly developed characteristics could cause unknown epidemiological diseases in humans, animals
or plants; if this happens, it could cause an ecological crisis. The uncertainty factor prevents scientists
from controlling outcomes and fully evaluating the potential damages.
(b) Because biotechnology can change organisms' molecular structures, and can alter the basic
hereditary substance, DNA, to improve organisms' traits, intervention via biotechnology could alter
hereditary traits and wreck havoc on an individual's genetic makeup as well as his or her descendents
because the inuences of biotechnology might not show up for several generations. Since the impact
of biotechnological experiments or products could take generations to surface, the uncertainty factor
becomes higher and it is dicult for scientists or manufacturers to decrease this uncertainty. Scientists
can only base their analyses on statistical ndings, and since so many unknowns exist, these statistical
cost-benet, or risk-benet analyses may be ineectual.
Similar problems have arisen from traditional technological products. For example, the environ-
mental problems revolving around DDT (one popular pesticides 20 years ago) have been attributed to
a myopic view of its benets without adequate consideration of risks44. DDT was not forbidden until
scientists found the poisonous elements in DDT are absorbed and accumulated in organisms. Similar
results occurred earlier in time with Thalidomide which caused many birth defects and cancer cases a
generation later, yet is was supposed to help women at risk of miscarriage carry their babies to term
and to reduce pain. Because the manufacturers and the government did not see that the negative eects
might surface in the long-term, thousands pregnant women took Thalidomide in many countries, such
as Japan, in 1960s. However, the Thalidomide caused gene mutation and deformed babies, which the
manufacturers and government regulators did not foresee. In order to prevent similar situations from
happening, and since biotechnological products need more time, possibly several generations, to prop-
erly assess the results more than is needed by traditional technological products, unique regulations are
necessary.
(c) Because modern biotechnology techniques allow the scientists to apply extremely subtle procedure
to control the production of biological molecules than ever before, and the eects on the organism or
ecosystem can be very slight and hard to identify. For example, the result might be a change in a
recessive trait that can cause hemophilia. The change is slight and recessive, and may not appear
until the two recessive genes are matched. These kinds of inuences are more dicult to discover and
evaluate. Existing risk assessment procedures and regulations that are designed to address obvious and
detectable inuences might not be able to prevent or assess results of these operations that have very
subtle inuences.
According to present regulations, products are assumed to be harmless if there is no positive evidence to
suggest or prove that they are dangerous or can cause ill eects. This further points to the fact that, there
are so many uncertainties in biotechnological experiments and genetically modied products that they must
14be closely regulated and assessed. \Care must be taken to distinguish between evidence for the lack of
risk" when there is little concrete or abstract evidence of negative eects.45 Biotechnology should thus be
held to stricter standards than simply limiting false negatives or false positives. In pure science, a false
positive is \an indication that a stated hypothesis is true when it is not46," and a false negative is \ a nding
that there is insucient evidence for a hypothesis which is correctly correct47." False positives and false
negatives, suggest that scientists, including biotechnologists can make wrong assumptions about the risks
and probability of the risks of genetically modied products. Generally, scientists do not consider tests of
negative eects as sucient to substantiate the hypothesis that a particular substance causes a particular
eect unless the results are statistically signicant, which means that there is only a 5 percent chance of
a false positive or a false negative48 (Fig.1). Therefore, if the probability of a potential risk is less than 5
percent, then the risk is not statistically signicant, and the scientist would assume that the negative result
would not happen. However, given the immense repercussions of biotechnology this standard might be too
broad, as even a 5 percent risk is a large risk if the results could impact an ecosystem or cause a deformity
or death, etc. In order to minimize the risks in biotechnology, stricter critical standards and the acceptance
of close to zero risk should be adopted.
2.5%
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Fig. 1 Critical Values
4.1.3. The Increasing Complexity of Biotechnology Development
Most scientists, scholars, and even politicians agree that biotechnology involves much more complex tech-
niques, has greater potential alter to biological and ecosystems, and more unknowns or risks than traditional
technologies. Besides, the uncertain inuences also increase the degree of the complexity. The complexity
makes it dicult to make proper risk assessments and evaluations. First, the inuences of biotechnology can
cause global eects due to countless and unexpected variables. Therefore, the risk assessment is impossible,
or at least dicult, because it is often dicult to simulate a similar environment and assess the long-term
multi-generation eects. Second, many genetically modied products have a special characteristic { the abil-
45Judith Miller, Environment Protection and Uncertainty: The Case of Deliberate Release of Genetically Engineered
Organisms, 7(2) Politics and the Life Sciences 142, 145 (1989).
46Id, 145.
47Id.
48Id.
15ity to reproduce { which can aect the world's gene pool and unbalance the delicate ecosystem worldwide49.
For example, opponents of genetically modied products are fearful that genetic material will cross over
into wild strains and reduce biodiversity by crowding out other organisms.50 Many external factors also
can inuence bioengineering experiments, such as weather conditions, wind currents, humidity, temperature,
and food supplies could aect the growth and reproduction of genetically modied organisms or the peo-
ple who utilize those products. Those external factors thus add to the complexity and unpredictability of
biotechnology. In some conditions, the inuences may not appear because the environment may not support
the growth and reproduction of genetically modied organisms. But if the scientists apply the traditional
regulations and framework to evaluate the genetically modied products and ignore the complex external
factors, they might have totally wrong conclusions. Third, the mobility and microscopic size of modied
microorganisms also increases diculties in managing and controlling them.
In comparison, generally, the inuences of traditional technological experiments and products are limited to
a small area and limited population. But genetically modied products might aect the whole world, and the
factory emissions might cause global warming even if they comes from some developed countries. Therefore,
the risk assessment and regulations are simpler, more predictable and easier than those of biotechnological
experiments and genetically modied products. Therefore, existing regulations and guidelines appear to
satisfy no one, and will likely increase in complexity.51
4.2. Market Failure
4.2.1. Information Asymmetry
Asymmetric information, meaning consumers have relatively weaken power than manufacturers and scientists
in gaining information about inuences of biotechnological research and genetically modied products, is a
serious issue in the assessment strategy and market operations of genetically modied products. The com-
plexity of the science behind bioengineering, specically for genetically modied products makes it dicult
for government regulators, consumers and others to assess the safety of the products and eects compared
to other technological products. According to Federal Food, Drug, and Cosmetic Act, the main consumer
resources for product information are product labels52. In this assumption, consumers can make rational and
ecient decisions by considering the information on the label. But this system is not workable for genetically
modied products market.
Since the potential harmful eects of genetically modied products are often uncertain, indirect and com-
plicated, simply labeling them at \genetically modied products" fails to inform the consumer of all of the
potential risks. The complexity involved in genetically modied products creates a \bounded rationality"
{ the limitation of an individual (in particular, a consumer) to make informed decisions. Some experts
question whether labels can provide consumers \useful" information to help them make rational decisions,
particularly with bioengineered products.53 Or the information would just only confuse the consumers, and
49Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 193 (1987).
50Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
L. J. 649, 649 (2000).
51Id, 183 (1987).
52Some experts argued the advertisements are another resources for genetically modied products. But the advertisements
are totally controlled by the manufacturers, and any consumer who believes an advertisement lack intelligence; no one in their
right mind believes ads nor should they. Thus, this article do not regard advertisement as a proper resources of information.
53Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
L. J. 649, 654 (2000).
16give them an elementary understanding of the genetically modied product and its inuences. The evalua-
tion of the eects of genetically modied products requires specialized information and knowledge. Besides,
because of the rapid development and novelty of this technology, even scientists have diculty accurately
evaluating or predicting actual inuences. Therefore, we can not expect that the current labeling system
will communicate adequate, useful and thorough enough information to consumers. Even if there is enough
information, it is also dicult to expect that consumers can exactly know the meaning of the information.
This could cause consumers of bioengineered food and pharmaceuticals to suer the consequences of their
uninformed decisions.
Another problem with the current situation is that scientists and manufacturers have more power and access
to information on biotechnological experiments and genetically modied products than government ocials,
consumer watchdogs and consumers have. Furthermore manufacturers have been known to reveal limited and
generally only positive information to the public and ignore the negative eects of their products. Take, for
instance, the cigarette industry. Some researchers and company insiders found that cigarette manufacturers
had been aware that the contents of cigarette such as nicotine and tar could be harmful to human's health.
But manufacturers and some scientists decided to conceal the fact that cigarettes might cause lung cancer
and other diseases because it would decrease their prots. Years later, independent scientists arrived at
the same conclusion and then the public had chance to test the risks. Comparatively, because genetically
modied products' inuences may be more dangerous and widespread than cigarettes' eect, the need to
balance the information asymmetry and fully inform the public of the possible eects and consequences
becomes even more imperative.
However, here is a trade-o situation. On the one hand, the current labeling system cannot supply sucient
information to consumers as discussed before. But on the other hand, more information does not guarantee
that consumers will enjoy more protection or make correct decisions with biotechnology products because
they do not have enough of a background in biotechnology or science in general to understand this complex
eld. For example, according to EPA's policy, evaluation and risk assessment of biotechnology processes and
products are dierent from the its practice of classifying the hazards of general non-biotechnology products by
product type, agent, and context, but by the technique by which it is produced.54 Besides, the information of
inserted/deleted genes characteristics is also required.55. But even though the information would be helpful to
prevent manufacturers from abusing their power, to improve the quality and depth of information provided to
the consumer, and to further eliminate information asymmetry, putting this information on labels along with
techniques applied is of little use for most consumers because it is too specialized Some experts also suggest
that the detailed information, such as applied techniques and characteristics of inserted/deleted genes, is not
necessary to reveal to the public because the information is dicult to understand and sometimes useless to
evaluate.
Therefore, an independent and professional committee that can evaluate the information and reveal some
simple and understandable data to consumers might be necessary, and a workable option for manufacturers
of biotechnology and pure scientists, along with government regulators and consumer watchdog groups. At
the very least, the government should set a standard and regulations making manufacturers of biogenetically
engineered products include the most important evaluation items and matters needing attention, and then
consumers can make more reasonable and ecient decisions in accordance to the standard rather than
blindly guessing. And the information on labels should not only be limited to the products' risks as current
54Amal Kawar, Richard Sherlock, Theoretical Issues in the Regulation of Genetically Engineered Organisms: The
Case of Deliberate Release, 7 (2) Politics and The Life Science 129, 129 (1989).
55Id.
17regulations dictate, but also include the processing risks.56
4.2.2. Externality
The issue of externality comes into play when examining legal and ethical issues surrounding this new eld
of biotechnology. Externality means that consumers and the general public do not reap prot accompanying
with cost when engaging in economic behaviors. But that often the community indirectly bears the cost
when environmental pollution occurs, or unsafe products are sold, or when unsafe manufacturing processes
cause environmental or other damage. For example, when manufacturer X produces a product to make a
prot, and in manufacturing the product, this manufacturer discharges contaminated water into a river, X
manufacturer generally does not pay the cost of pollution, unless sued by the consumers or residents living
in the polluted area. Comparatively, the residents living near the factory, who cannot reap any prots from
the manufacturer's economic behavior, should not have to bear the eects of the pollution or spend money to
remove the pollution, but they often do bear the costs in terms of health risks and public clean up costs paid
for by their taxes. Therefore, this product has \external costs" because people who are engaged in economic
behaviors are often forced to pay for the manufacturer's unsafe processing costs. Similarly, when company Y
plants many owers to make a prot, the surrounding residents can enjoy pleasant fragrances and beautiful
scenes at no cost. This then is an external benet in Y's economic behavior because the residents can realize
a free prot from Y's production.
Unlike other traditional products, because of the complexity of bioengineered products, and the uncertainty
involved in outcomes and the long-term eects on reproduction, genetically modied products have stronger
externality factors. For example, genetically modied products might require fewer pesticides, and conse-
quently cause less environment pollution. These benets would not be reected most likely in a lower price to
the public due to the high costs of manufacturing. Comparatively, the residents around the farms who have
nothing to do with the production would enjoy a cleaner and safer environment. Then genetically modied
products also have external benets. On the other hand, these same genetically modied products might
violate the ecological balance, not only in the farm's immediate region but the negative eects could aect
the ecosystem and biological organisms well beyond the region, across the country and the world. These
costs also would not reect the product's price either. Hence, there are external costs in the production
process because the residents who might never have a chance to use the genetically modied products are
forced to pay the cost.
The external cost might cause common and frequent market failure of biotechnology. And the failure could
not only cause ineciency but could also seriously aect the world's ecology and delicately balanced environ-
ment. Therefore, we will discuss more about the inuence of external cost on genetically modied products
market below.
In the free market, \social marginal benet (SMB)" should be equal to \social marginal cost (SMC)" and
achieve the most ecient resource allocation/distribution. But when there is external cost in the reproduc-
tion of genetically modied products, the SMC will be greater than \private marginal cost (PMC)" (see Fig.
2). Manufacturers can underestimate production costs and set lower prices because the cost does not reect
on their production costs. For example, manufacturers of both genetically modied products that can cause
environmental damage or harm to humans and animals can ignore the potential cost of risks such as toxicity
and environmental pollution when producing genetically modied products. Especially when the inuence
does not appear until several decades later, or the causation between harm and products is not clear. Thus
56Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
L. J. 649, 659 (2000).
18it is unlikely manufacturers would add these costs to their production. Therefore, if governments do not
intervene with market operations, and let the free market dictate the price and quantity, the maximum
quantity decided by the free market (Q2) would be greater than the maximum quantity decided by social
welfare (Q1). Ant there will be a deadweight loss resulting from the dierence between the Q1 and Q2 (area
abc in Fig 2).
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Fig 2. External Costs
The loss includes not only inecient economic behavior but also damage to the ecosystem, including poten-
tially loss of human and animal life. In this scenario, consumers can underestimate the real price and the
potential cost of a product due to the free market price (P2), which does not include external costs, and
is lower than the real price (P1). Since consumers, no matter how purposely or not, do not see the whole
picture, that is, the potential costs, they generally use cheaper products, failing to see the long-term eects
that their decision entails.
Therefore, even if the genetically modied products pose risks to the environment and the ecosystem, the
market does not reect these cost and thereby adjust the demand and supply curve to achieve an equilibrium
point that is the most ecient condition of social welfare (point b). Because the price does not reect external
costs, consumers would underestimate the real cost in using genetically modied products. They can be,
in eect, changed when buying cheaper products without regarding the actual harm that they can cause.
Therefore, the utilization becomes more than the maximum quantity decided by the social welfare, and
cause more pollution on the environment and more violation on ecological balance. On the manufacturers'
side, because the cost is shared by the consumer, the apparent cost is less than the real cost. And because
manufacturers can underestimate the cost, they can produce more products and cause the actual production
quantity (Q2) to be more than the maximum quantity decided by the social welfare (Q1). Both consumers'
and manufacturers' economic behavior errors (lack of foresight and concern) can cause ineciency and
damage to the ecosystem.
Therefore, in attempting to resolve the potential market failure, the genetically modied products market
might not be as free as the market of other traditional products, and thus, adds another reason to why the
government should initiate regulations and license fees and taxes to internalize the external costs.
4.2.3. Social Justice
Some scholars also argued that the broad application of biotechnology might create a \genetic underclass."
For example, some people such as mid-class laborers and the poor may not be able to aord the more
expensive products, and buy the cheaper ones, that may have more chemicals or have undergone genetically
modied processes that could harm them or their children or children's children. They have no choice but
buy cheaper genetically modied products and neglect the potential risks. Therefore, if the government does
20not address the potential risks and lets genetically modied products enjoy the same trustworthy safety as
non-genetically altered products, theoretically, the government would be allowing unfair treatment of mid-
class laborers and the poor.
These unfair situations can also occur in international relationship. For example, countries that have strong
biotechnological industries can export their genetically modied products, and other \unsafe" products
to poor countries that comparatively have weak biotechnological industries, and disregarding the potential
threats of these products to humans and/or the ecosystem crisis. For example, in the 1960s, when thalidomide
was in the evaluation process in U.S., it was sold by American pharmaceutical company to Japan and
other developing countries because the latter did not have strong pharmaceutical industries and nor a strict
evaluation system. Therefore, the drug claimed hundreds victims in Japan including the pregnant women
who took thalidomide, and the babies who were born with deformities. This unequal treatment, or at best,
thoughtless economic transactions can cause harm to people and environments of developing and third world
countries, in part, because the developing countries do not have sophisticated evaluation systems and are
desperate for certain products or industries. Over time, the damages caused by biological experiments and
the export of genetically modied products can spread from one country to another and aect the delicate
global ecosystem.
I assert that in order to resolve these problems, more regulations are necessary for bioengineered products
and biotechnology practices because (1) the current regulatory system cannot ensure the safety of genetically
modied products, and (2) there are only few international standards for adequate evaluation of products
and processes that can cross national borders, but it is obviously not enough. Especially, most U.S. domestic
statutes care about the eects of genetically modied products and biotechnological research within U.S.,
but do not seriously regard the inuences on other countries. Although statutes such as the Noxious Weed
Act, the Federal Seed Act and Endangered Species Act authorize the USDA and Department of the Interior
(DOI) to monitor and control the import of plant material and animals, these regulations are limited to
the domestic arena and are trying to prevent potential dangerous products from being imported from other
countries to U.S. There is no regulation aimed to prohibit U.S. corporations from exporting potentially
dangerous products to other countries. Some experts argued that those regulation of export should base
upon the statutes of the importing countries. U.S. government does not have obligations to monitor the
potential risks for the people in other countries. However, since the biotechnology has unbounded inuences
on environmental and ecosystem as discussed before, should the western countries still adopt the conservative
attitude toward the regulations of biotechnological research and genetically modied products.
4.2.4. The Proud of Science Challenge
Science is not neutral and independent as some people assert. Like a two-sided blade, science can improve
human life and welfare on the one hand, but its misuse might also cause negative outcomes. Throughout
history, many tragedies have resulted from the over condence of scientists especially following the industrial
revolution. Many scientists have believed they could improve human life simply by employing \omnipotent"
scientic technology, which they believed would be benecial for society, and individuals' sacrice is worth
and necessary. Then in the intentional operation by a person with illegal or selsh objectives, the logics
and statistics are the basic and only values without regarding the importance of human life, dignity and
social values, and science became the highest values which violated basic human rights. Some governments
and manufacturers even violated human rights and seized interests that operated in guise of science. For
example, early genetic researcher in the beginning of the twentieth century developed and promoted the myth
of eugenics { a theory that \superior species" and \inferior species" exist. Furthermore, some governments
such as Germany Nazi used scientic techniques to screen the \inferior species" and as a rationale to execute
21people. In essence, the Nazis used science to justify inhumane policies and practices such as the slaughter
of 6 million Jews as along with discrimination, compulsory ligation, and compulsory abortion to \improve"
the species. Genetic engineering techniques can also be used by autocrats and terrorists to \improve" the
biological and chemical weapons to achieve destructive consequences. For example, Japanese trop used
Chinese victims in biological weapons test in World War II.
The current U.S. regulatory system has many regulations to reduce the misuse of scientic techniques. But
some experts argue that these might not be adequate to prevent the misuse of biotechnology. First, current
regulations do not specify who should have the power to handle and control these new and potentially
harmful technologies. This issue becomes key when the technology can aect human life, and the world's
ecosystem. Some Hollywood movies such as Jurassic Park have described possible disasters that could
result if the wrong people use and abused these newest techniques. Second, in order to eciently regulate
the abuse of biotechnology, government's power should be expanded. But the problem lies in the balance
between the expansion of the government's power and individual and free market freedom. This issues needs
further examination (see discussion infra part 5.1). Third, the current system has placed much emphasis on
the protection of human's life and health values. But some scientists are used to applying quantiable and
measurable standards to see the issues of human's life and health values, such as morbidity and mortality,
without regarding the core of human dignity as being strongly related to non-physical evidence, such as
social psychology, and moral and religious beliefs. Besides, the government also ignores the balance between
the development of science and the protection of dierent life forms such as animals and plants and the
potential risks and inuences on these from human interventions.
5. The Disadvantages of More Biotechnology Regulations
5.1. Constitutional Issue { Freedom of Biotechnology Researchers and Market Enterprises
The constitutional issues related to increasing the U.S. government's regulations on biotechnology focus
primarily on biotechnological experiments. There is not much debate about whether the government should
regulate genetically modied products because these products will enter the market or already exist in the
market, so it is reasonable to expect the government to protect people's safety and health.
But the regulations on the biotechnological experiments before the production of genetically modied prod-
ucts raise concerns because some may fear that the regulations might violate the independence and freedom
of academic research. Regulatory issues were initially framed by the process versus product debate, where, in
general, biotechnology critics argued that all genetically modied products should be regulated via new leg-
islation because they result from genetic modication, and thus regulations of biotechnological experiments
are necessary. Biotechnology proponents argued that genetically modied products should be regulated only
on the basis of specic product characteristics57, and those characteristics would not show in the period of
R&D until the manufacturers start producing them.
Most discussions of academic freedom center on the teacher as source or purveyor of the knowledge, ideas,
and viewpoints that are to be explored, developed, and disseminated through the academy.58 Comparatively,
scientic expressions, experiments and theories, often put forth in universities and commercial laboratories
in the U.S. have no constitutional protection under the First Amendment of the U.S. Constitution, no matter
57Les Levidow, Susan Carr, Normalizing Novelty: Regulating Biotechnological Risk at the U.S. EPA, 11 Risk: Health
Safety & Env't 9, 13-14(2000).
58E. Edmund Reutter, Academic Freedom Rights of Students: Some Recent Cases, 108 Ed. Law Rep. 1, 1 (1996).
22if the expression is communicated via spoken or written words, or via experimentation.59 Some experts have
argued that neither of the two components of scientic expression { (1) formulation and communication of
ideas via spoken and written words, and (2) formulation of ideas via experimentation { has express con-
stitutional protection under the First Amendment. Although a persuasive argument can be made that the
pursuit of knowledge is implied in the rst amendment protection of free speech, such protection would
encompass only the communicative aspects of scientic speech.60 However, some scholars have made a per-
suasive argument that scientic experiments are hardly distinguished from scientic speech which is covered
under First Amendment protection.61 In addition, there is no way to develop scientic inquiry without
scientic experiments. If \research freedom" is not included in the protection of the rst amendment, and
the government can forbid some types of research and essentially violate \research freedom", it is hard to
see whether scientic speech is actually protected by the U.S. Constitution. According to some countries'
constitutions, such as Germany's62, Japan's63, and Taiwan's64, research freedom is viewed as the core of
academic freedom, and protected as a basic right. In these countries, scientists and scholars have total
freedom to choose any topics, procedures, objects, time and place to do the research. And there is strict
standard to follow if the government wants to regulate the academic speech and behavior. Based on this, at
least one commentator argues that experiments are expressions65, and that scientic expression constitutes
academic freedom and thus should be protected under the rst amendment guaranteeing free speech.
When a government tries to \abridge" or curtail freedom of scientic research, its reasons for doing so can
be placed into two broad classes. The rst is restricts freedom because of its due to content; that is, because
of the ideas or information contained in it, or because of its general subject matter. The second reason for
curtailing freedom of expression rights is when the government seeks to avoid negative repercussions not
connected with the content, but the government's regulation has the incidental by-product of interfering
with particular communications. For example, in Gitlow v. People of the State of New York66, the Court
described that right of free speech is not absolute right to speech without responsibility, and under police
power state may punish utterances inimical to public welfare67. In Rice v. Paladin Enterprises, Inc.68, the
Court also argued that if a publication could be found to have no other use than to facilitate unlawful con-
duct69, the speech creating a signicant societal harm is enough to give rise to a compelling governmental
59Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 185 (1987).
60Id, 185-86.
61Id, 186.
62Article 5 Section 3 of German Constitution.
63Article 23 of Japan Constitution.
64Article 11 of Republic of China Constitution.
65Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of Biotechnology Research, 17 Envtl.
L. 183, 186 (1987).
66Gitlow v. People of the State of New York , 268 U.S. 652, 45 S.Ct. 625 (1925).
67Id at 630.
68Debs v. United States, 249 U.S. 211, 39 S.Ct. 252 (1919).
69Rice v. Paladin Enterprises, Inc., 128 F.3d 233, 255 (1997).
The fact of Rice is that James Perry murdered Mildred Horn and Janice Saunders by shooting them through the eyes and
strangled Ms. Horn's eight-year-old quadriplegic son, Trevor. It appears that James Perry was not acting without assistance-a
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23interest in proscribing such speech70. But the limitations must be reasonable71, and Holmes argued that
the intent could be inferred from the natural tendency and probable consequences of the speech, as well
as suggesting that the encouragement need not be direct72," and \the jury ...could not nd the defendant
guilty for advocacy of any of his opinions unless the words used had as their natural tendency and reasonably
probable eect to obstruct the recruiting service, and unless the defendant had the specic intent to do so
in his mind73."
In the case of biotechnology, we have to consider whether the state's interest in protecting the public health
and the environment is \suciently important" to justify regulating the \nonspeech element of experimenta-
tion."74. Some experts claim that biotechnological experiments meet the requirements of scientic expression
as set out in the First Amendment. First, because of the uncertainty, complexity and long-term inuences
of biotechnology, the content of scientic experiments is a sucient reason for the government to regulate.
Second, because biotechnology has a potentially strong eect on social values, then it is also reasonable
for the government to regulate biological experiments to prevent the negative eects of the \by-product."
Therefore, the regulations that control biotechnological experiments are not against the Constitution.
Therefore, regulations aimed to control or limit biological experiments might potentially violate the indepen-
dence and freedom of academic inquiry and scholarship. However, because the state has a legitimate interest
in protecting the environment, and the public's health and safety, the state interest should be \suciently
important" to justify regulating the nonspeech element of biological experimentation.75. But the state has
obligations to carefully address the limitations because they might easily violate people's right of free speech
and academic freedom. Valerie M. Fogleman suggested that if regulations were narrowly drafted to address
only safety measures, a rational basis for the regulations would probably be sucient. But if regulations
actually served to suppress knowledge, however, the state would probably be required to show a compelling
interest for the regulations.76
5.2. Economic Loss
Many biotechnology manufacturers also argue that more regulations are not necessary due to competing
interests and competition in the market. In other words, the free market and dierent interest groups will
nd a balance and ecient point rather than the government's regulation strategies. Manufacturers can bear
their products being tested by the routine procedure to assure their safety to humans line because via the
assessment system, they can in advance test the safety of the genetically modied products and avoid more
compensation requirements if the product harms people or the environment. However, if the experiments
or research of the products also need to be regulated in advance, manufacturers suer not only freedom of
developing the products but also the loss of the competition with other manufacturers, especially foreign
manufacturers with looser regulations. For example, President George W. Bush declared that the publicly
funded research will not be allowed to carry out any embryo experiments. The limitation no doubt will
substantially restrict the development of biotechnology in the embryo area. However, in some countries
such as China, embryo experiments are allowed because the government does not regard an embryo as a life
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24form, and there is no conict between biotechnology and moral/religious values. Therefore, the regulations
in China become more loose than in U.S. And the dierent national regulations consequently may decrease
competition in the biotechnology market in U.S.
Besides, if the public requires detailed information about biotechnology products and procedures, and if the
government enforces regulations requiring full discloser of dangerous ingredients and processes, or the state
tries to regulate biotechnological experiments before the production of genetically modied products, then
some manufacturers will suer by having to reveal their business secrets, and condential and proprietary
information to competitors which could decrease or deprive them of potential prots. And this requirement
could discourage manufactures from investing more resources in the research and development of genetically
modied products. This could then cause not only the loss of economic prots but could also stall the
development of biotechnology.
Therefore, many biotechnology manufacturers believe that regulation should take place after research is
completed but before commercial production and marketing begins. They believe that the regulations should
focus on the safety and reaction procedures, but not on the contents of the experiments. In other words, they
believe that the government should only ask the manufacturers to set safety standards to prevent potentially
dangerous experimental materials from entering the environment and a cleanup procedure to decrease the
harm if the harmful materials touch the environment. Some advocates of biotechnology freedom argue that
the government should not enact more regulations in terms of which biotechnological experiments are allowed
and which are not, where the biological experiments should take place, and under what circumstances they
should be allowed.. Many people believe that the current regulations such as the assessment of environmental
inuences and risk assessment of drugs and food are enough to protect the public's safety and health.
5.3. Government Failure
According to regulatory theory, more regulations, including the banning of some types of biotechnological
experiments and products, would not necessarily ensure that genetically modied products would not enter
the market, but rather would create a black market for the products. As a result, the government would
face more problems in monitoring the risks and safety of genetically modied products in the black market,
and furthermore, the free market would be violated.
Besides, the price of genetically modied products might increase because the supply are limited and de-
creased. There are two situations might happen. First, the increased price of genetically modied products
would become higher than the price of the non-genetically modied products, and everyone will use the later
products. There is no much debate in this situation. But if the increased genetically modied products (see
point A' in Fig. 3) is still lower than the price of the non-genetically modied products (see point B in Fig.
3), the mid-class and low-income laborers would still buy the genetically modied products because they
would be less expensive then the normal products.
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275.4. Social Justice { Relativism
Genetic modication processes and genetically modied products can oer consumers \lower-cost products
that taste good, are easy to transport, and have increased shelf life and nutritional value."77 This is appealing
to all classes of people, including the middle-class and low-income laborers with xed and scarce resources
for their multiple needs such as food, health care services, work training, and housing. Therefore, buying
cheaper and larger quantities of genetically modied products would alleviate the nancial pressures facing
mid-class and low-income families.
Here is a trade-o situation. Even though the price of genetically modied products is low, but the safety and
inuences are uncertain under current regulations. But more regulations on genetically modied products
also means that the manufacturers have to spend more to meet the regulatory requirements, which they will
pass on to consumers. Thus, if stricter regulations would be enforced, they would have to spend more money
than before the new regulations and they would suer more risks consequently creating a social injustice.
If the goal of legal reform in the biotechnology eld is to protect the public's health and safety, then
more regulations of genetically modied products and biotechnological experiments are necessary. But if
the regulations are based upon some interest groups' political or religious preferences or values, then the
regulations would deprive the public, including mid-class and low-income laborers' right to access cheaper
and better products. And if society and the government has to spend more money on normal products,
consequently they would have few resources in medicine, housing and other basic life requirements.
In addition, according to existing evidence, there is no clearly demonstrated health or safety problems related
to genetically modied products. Thus far, the eects are slight or based on moral objections. For middle-
class and low-income laborers, the weight of the uncertainty and slight eects is much less than the problem
of starvation and sickness. Even though biotechnology has uncertain, complex, and possibly long-term
inuences on health, the middle-class and the poor might not care because the inuences might happen long
after, and they would not survive at all if they cannot get sucient food. It is impossible to persuade the
middle-class and lower-income family to buy the expensive natural food instead of cheap genetically modied
products just because they \might" cause an \uncertain" disease at age \75". For them, the immediate need
is gaining cheap and nutritious food. Many experts also have predicted that the world's food supply will
be threatened in future decades because of the global warming eect and increasing population. And the
increasing price of food might cause unfair distribution to poor nations. Many proponents of bioengineered
food believe it is a solution for meeting the food needs of a growing global population while minimizing the
amount of arable land needed for agriculture, and reducing food costs.
Even though some opponents of bioengineering have argued that more regulations of biotechnology are
needed, some experts claim these reasons are improper and due to subjective moral and religious values.
They claim that the regulations should not involve issues of morality. These proponents of biotechnology
argue that when the government considers the safety of biotechnological experiments and genetic modied
products, it should not base its regulations on \middle-class morality" or \religious values." The government
should consider only the impact of biotechnology on human health, safety, and environmental protection and
laws should be decided by Congress, which represents the people and not by the executive branch or the
courts.
Therefore, more regulations can protect the poor and the general public from unsafe genetically modied
products, but on the other hand strict regulations could also limit the poor people's access to sucient
77Julie Teel, Regulating Genetically Modied Products and Process: An Overview of Approaches, 8 N.Y.U. Envtl.
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28and nutrient food. When the government tries to set more regulations on biotechnological experiments and
genetically modied products, it cannot neglect the needs of all of society including the working class and
the poor. If the government forbids biotechnology experiments and genetically modied products without
regarding the needs of the poor it could \attend to the supercial and neglect the essentials." For the U.S.
government, its duty to protect people's right to life is important. In essence, the biotechnology issue is
complex and unpredictable. On the one hand, its development could cause an ecological crisis and on the
other hand, it could possibly save many poor nations from starvation. Yet adding more regulations could
cause social injustice and violation of human rights, but not adding them could cause social injustice and a
violation of human rights if the poor end out using products that are not adequately tested. Added to this,
without strict regulations, bioengineered products and processes could cause a worldwide ecological crisis.
Thus, the government { politicians, policymakers, lawmakers and scientists and public interest advocates {
must carefully consider the potential benets and risks.
5.5. Feedback and Diversied Regulatory Methods
According to opponents of biotechnology, more regulations would prevent genetically modied organisms
from destroying the ecosystem, and protect varieties of organisms in the ecosystem. But according to the
other viewpoints, more regulations might result in the deterioration of the world's delicate ecological balance
because we could over-farm the land and use too many pesticides to produce enough food for the world's
growing population. For example, banning or discouraging the use of genetically modied products would
cause more exploitation in suburban and rural areas and contribute to the destruction of forests to grow
enough crops to supply the world. And the agricultural expansion could cause the extermination of desired
organisms varieties.78 Because regulations that aim to protect organism varieties, inversely could destroy
some organisms' environment.
The conicts for policy and lawmakers exist everywhere, especially in developing countries, where a stable
food supply is more important than the protection of the ecological balance. However, the interests of more
ecient farming and development clearly do not always assist developing countries as we have seen with the
situation destruction of the rain forests in South America, where the government has allowed businesses to
cut down trees in exchange for economic growth. Clearly careful analysis of the costs-benets and benets-
risks must be carried out before any laws are established.
More regulations could preserve the ecosystem, but they also might indirectly cause a loss of biodiversity.
Genetically modied products could also help to feed millions of people and help preserve and enhance
life on earth. But how to resolve the potential risks is a question policymakers and lawmakers must ask.
Manufacturers argue that the resolution should not be more regulations on biotechnology experiments and
genetically modied products. They think that the adequate reservation methods would be more ecient to
protect the environment and human health, and would also support the development of the economy. For
example, the government can \create buer zones or refuges for non-resistant insects that will dilute the
resistance built up by insects in the genetically modied organisms," or build \germplasm banks" to prevent
an organism from being eradicated by a disease or a genetically modied organism.79
These measures would not only delay the implementation of biotechnology techniques, but also reduce the
threat to the ecological system from the new biotechnology. And they also believe that biotechnology could
help to preserve the biodiversity. Therefore, they argue, more regulations on biotechnology are unnecessary
and incapable of resolving the current threats caused from biotechnology.
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296. The Contents of Regulations of Biotechnology
Based on the above discussion, I believe that biotechnology must be regulated but to an appropriate degree.
However, two questions need to be decided: (1) who will regulate, and (2) what issues should be regulated.
6.1. Who Will Regulate { Is Self-Regulation Enough?
6.1.1. Some Scientists' Viewpoints
Some scientists believe that biotechnology should be regulated, but they also wish to maintain
their freedom to experiment and explore the array of elds open to biotechnology, from stem
cell research to agricultural applications of genetically modied plants. Many scientists would
agree to be regulated by society or the government.
Many scientists argue that the decision-makers on biotechnology regulations require specialized scientic
knowledge; they believe that to be rationally discussed all \participants should understand the subject
matter."80 Generally, scientists do not want the public to intervene in their jobs. It is generally believe that
the fears of those opposed to biotechnology are based on emotional and political forces and that they lack
scientic evidence. They believe that the public overreacts without complete and detailed statistics and proof,
or at least unproved reports. For example, an author of the \Berg letter" which recommended the regulations
of biotechnology admitted the letter \was based on emotional instead of scientic data."81 However, the
public was inuenced by the report and as a result, following the letter, there was an upsurge of public support
for the regulations, including the NIH's guidelines on biotechnological experiments. Throughout the past
decade, scientists have spent much eort in countering the public's fears that biotechnology is not dangerous
as what the public thought, and in proving the public has had established stereotype about biotechnology
and hardly been changed even when most scientists believed that the biotechnology or biotechnological
modied products are harmless. In addition, scientists advocate for independence and freedom to research
and believe their work should not be controlled by politics, irrational fears and social and religious values.
80Id.
81Id, 189.
306.1.2. The Public's Viewpoint
Portions of the U.S. public wants to have more control over biotechnology based on founded and unfounded
facts and fears of biotechnology's danger that the scientists did not reveal.82 The public's suspicion is
due to past scientic miscalculations about the safety of processes that have resulted in accidents such as
Chernobyl and the tight relationship between the scientists, manufacturers, and politicians. Large segments
of the public believes that the scientists will not voluntarily reveal the danger of biotechnology processes
or biologically modied products because of self-interest. The belief is not entirely groundless. No doubt,
the information about the biotechnology's ill eects, and the call for stricter regulations threaten scientists'
and manufacturers' self-interest. Scientists are not independent and neutral especially when they work for
the manufacturers, or they can benet from selling genetically modied products. Therefore, scientists and
manufacturers' credibility is weakened when they argue for self-regulation and relaxation of regulations.
The public's participation in assessing the risks and benets of biotech products and processes would help
to increase the credibility of scientists' evaluation, reduce the public's mistrust and prevent manufacturers'
abuse of information power. It would also prevent the scientic community's and the public's perception of
risks becoming polarized83.
Second, the public has the right to participate the regulations. Public participations in scientic discussions
should not be prevented or discouraged just because of the complex and dicult to understand scientic
nature of the topic. Even though the decisions are related to technological and scientic issues, the public
is still \not satised by what appears to be elitism and arrogance on the part of scientists84." The scientic
nature of biotechnological experiments and genetically modied products should not grant the scientists the
complete authority to make decisions, and forbid the public's participation on the basis that the public can
not understand such complex issues. In fact, the public can educate itself if need be and can take into
consideration the opinion of many \experts" whose opinions might dier. The public might need to respect
the scientists' opinions, but need not to entirely accept their decisions without any preconditions. Besides,
scientic knowledge belongs to everyone, not merely the scientic community or the manufacturers. The
public also needs to express their ideas, and \only then can a meaningful exchange of ideas take place85."
Third, the public has right to require a safe environment and standards that match its varied values but
not entirely follow the scientists and manufacturers' descriptions. The development of research and modied
products is indirectly based upon the desires and needs of the public which often wants a more convenient and
comfort life. When the public has a vivid imagination of mad scientists creating Frankensteinian monsters,
or of using live human beings in ghastly experiments, they \demand input into research decisions."86 I
believe that these the demands should be respected. Scientists and manufacturers should not ignore the
public's fears, even if it is unreasonable, by advocating for independence of scientic expression from the
public's control.
6.1.3. Conclusion
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31The public needs accountability from the biotechnology industry and is making more vocal demands for it to
meet health and safety requirements. Accountability cannot be achieved without the public's participation,
especially since biotechnology could potentially destroy the global ecosystem and harm human and animal
life. In addition, it is tightly related to the social morality and religious values. The public has the right to
regulate potential risks to its own safety, rather than trust in self-regulation by the scientic community.87
Besides, because the inuences of biotechnology can be so widespread and uncertain, that any major errors
could create massive ill eects. Thus, the public has the right to set its own criteria to regulate its aairs.
Many advocates believe that scientists' self-regulation in the biotechnology realm, whether in experimental
processes or in genetically modied products, does not provide enough safeguards and checks and balances
to the public. However, decision-making without scientists' participation is not adequate either because their
expertise and insights can add value to the debate and to regulations.
6.2. What Issues Should Be Regulated?
Because of biotechnology's close relationship to social values, legal analysis must extend beyond physical
risk. The government and legislators must consider biotechnology's impacts on both physical risks and
social impact and ethical considerations88.
6.2.1. Social Risks and Ethical Considerations
Some experts argue in the context of \social risk" that \knowledge of biotechnology is viewed as dangerous
or against the public interest," and \biotechnology research is viewed as morally wrong" because of the fears
about future abuse of biotechnology.89 Based on this thinking, many limitations have been adopted not
due to scientic risks but due to what is viewed as \moral incorrectness" of biotechnological processes and
products. For example, President Bush has banned federal subsidies to support promising research into stem
cells that have been extracted from embryos on the moral premise that it is improper to use human embryos
for research because they once were living creatures; fears also exist they embryos that could survive could
also be used for research.
However, many scientists have complained that the tighter policy will cause the U.S. to fall behind other
countries in the development of biotechnology, especially because some countries allow it because they do
not value morality arguments, nor they do not care about the tensions between social values and scientic
endeavors. It appears though that the dierence between countries pursuing biotechnology development will
be obvious in 10 years. For example, because of dierent cultures and religion, China does not believe that
the embryo is a form of life and thus allows research using embryos (see discussion supra part 5.2).
Besides, because the fear of \social risks" not only apply to biotechnology experiments but also genetically
modied products, the extreme and broadest view of \social risks" could also cause the collapse of biotech-
nology and related industries. Because U.S. society's hostile attitudes toward biotechnology could cause the
government to implement stricter regulations for biotechnology this could further impede the expansion of
the industry. Then the industries would move to other countries to produce more and cheaper genetically
modied products.
Therefore, the impacts of biotechnology on social risks are unavoidable, but it is also counterproductive to
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32excessively expand the denition of \social risks" because the abuse of social values may become obstacles for
economic and biological development, and the subjective nature of social values will cause the scientists and
enterprises do not know exactly what course to take. It is hard to deny that a policy could be a mistake and
cause the tragic environmental or biological disaster that would upset the social order if it is mainly based
upon pure scientic evidence and without considering social and moral values. But the extreme emphasis on
social values can also cause paranoia block the development of science and economics, and impede the free
ow of scientic thoughts and creativeness, just like the Middle or Dark Ages. I believe that the weight of
scientic evidence and social values should be placed in careful balance. Sociological and ethical judgments
are important but they are value judgments in the evaluation or decision-making process of biotechnol-
ogy regulatory system90, and not scientically based at all times. These hose judgments should somehow
align with the public's interest and scientic proofs. The absence of value of science per se does not mean
that ethical judgment should become the only value that inuences decisions on regulations. The unknown
knowledge and unknown inuences of products need to be rationally evaluated by quantiable methods and
qualied sources in dierent domains including the scientic, social, moral, legal, environmental safety per-
spectives, and economic development. And only under such a complete and diversied consideration, can
the cost/benet analysis be acceptable.
In my opinion, there are two ways to address the \social risks" issue. First, \social risks" should be limited
in the most basic and destructive conicts, and have dierent weight in dierent areas. Namely, the ideas
of social values should not endlessly expand, but be limited in the most important beliefs that the society
believed. For example, the Catholic regards it is extremely immoral to not treat embryo as a life. Because
dierent groups have dierent values and emphasize dierent issues, the weights of dierent social values are
not all the same. For example, environmental risks should not become the main concern when biotechnology
applied is to plants. Discussions and safety evaluations of genetically modied plants and medical proce-
dures should be based solely on scientic statistics, nor should they be based solely on ethical codes. Neither
should moral issues become the most important characteristics in assessing whether embryo experiments
should be approved. Second, in order to lighten the negative eect of \social risks" on the development of
biotechnology, \social risks" should not be the only standard in setting regulations. Introducing scientic
data about the benets and damages could eciently decrease the inuences of \social and environmental
risks."
Third, in order to avoid the `social risk' become an ideal thought without thinking the diculties in practicing
which the general public might face, the weight should not be decided by scientic elites, interest groups, or
legislators, but by the general public. For example, the leading opponents of biotechnology might argue that
genetically modied crops could change the biological world to a \designed" world and that biotechnology
knowledge should be put in \a dierent path ...whose goal is to foresee how better to participate with rather
than to dominate nature91." But the hungry people in Africa and their governments might be strongly against
this viewpoint because their main concern regarding biotechnology is that it can produce more and cheaper
crops to resolve their starvation problems. If there is no signicant and clear danger to the environment
or to human and animal safety, they would not want to give up those technologies just because of \social
risks." In this kind of decision-making model, the viewpoints of opponents, manufacturers, scientists, and
the general public should be considered together.
Therefore, when governments try to establish regulations, they should consider dierent interest groups'
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33opinions and set dierent weights got social risks such as its potential inuence on the global environment,
family relationships, moral values, and religious beliefs. For example, opponents can argue that biotechnology
could \lead to a `designed' world rather than a natural one", while scientists can argue that the risks are
very small, and the general public can argue that they want cheap products more than so-called \politically
correct" morality. In this way, the government can make proper decisions on regulating biotechnological
experiments and genetically modied products taking into consideration signicant environmental and social
risks.
6.2.2. Physical Risks
According to Valerie M. Fogleman, the physical risk in biotechnology experiments has at least three potential
outcomes: (1) construction of a unique organism not existing in nature, (2) the organism's establishment in
the environment, and (3) harm caused by the novel organism to the environment and/or people.92 If any one
of these three components was shown to be totally false, the biohazards of biotechnology would be proven
unfounded.
However, these three outcomes are just general descriptions. Clear standards to judge by which evaluate the
contribution of biotechnological components are not yet clearly established. The undened and indenite
standards also cause the regulations to be relatively loose. For example, the regulators consider \a absence
of evidence is not evidence of absence" because \it is virtually impossible to prove that risks do not exist in
scientic experimentation", and \risks inherent in direct release experiments cannot become apparent until
after an experiment is conducted."93 But the loose regulations might not t biotechnology experiments and
genetically modied products, and may need to be changed. There are three reasons why \physical risks",
unlike \social risks", should be stricter and with no gray areas:
(1) The characteristics of physical risk are not like those of social risks. Physical risks are specic,
objective and quantiable. Social risks are more subjective, indistinct and might be controlled by
religious or interest groups. Since physical risks can be objectively evaluated by quantiable data,
then it is not necessary to fear that the stricter standards would obstruct the normal development of
biotechnology, or excessively interfere with the freedom of research and the operation of the market by
means of moral or religious values.
(2) The inuences of physical risks are directly related to the well-being of humans and the environment.
And because of biotechnology's close relationship with human beings and life, it is necessary to set
stricter standards to regulate the physical risks.
(3) The risks of biotechnology might not show up until the next generation because of the uncertainty
and complexity involved in altering molecular processes. I agree that \risks in direct release experiments
cannot become apparent until after an experiment is conducted," but the problem is that the risks
might not become apparent even when the biotechnology experiments are nished or genetically modied
products are in the market. As was discussed before, the eects of biotechnology are uncertain because
the impacts might not be appear until the next generation. Besides, the interactions between genetically
modied and unaltered organisms and the environment, are not clear. It is also hard to set a clear
and denite mechanism to test the causation, or to identify whether the inuences were caused by
biotechnological techniques. Because of the uncertainty and complexity, the loose standards ??
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34Therefore, the standard of physical risks should be stricter, meaning that if, after excessive evaluation, if
biotechnological experiments or genetically modied products \might" be related to the physical risks, then
the experiments and products should be regulated or prohibited without regard to the causation. There are
several methods to prevent potential physical risks. One method which was discussed in this article before
is limiting \false negatives" or \false positives." Normally, scientists would not consider the tests of negative
eects as sucient to substantiate a hypothesis that a particular substance causes a particular eect unless
the results are statistically signicant. And statistical signicance is decided by the corresponding critical
point, the probability of physical risks. But here I suggest that the critical value should be stricter, or less,
than the normal value; meaning that the probability of physical risks of a genetically modied product should
be less than the normal corresponding value. Only then can the product can be considered safe. The other
value is in regard to the \absence of evidence" as the \evidence of absence." Using this logic, scientists and
manufacturers would be more motivated to prove the causation between the inuences and novel products.
7. Conclusion
Regulating biotechnology research and genetically modied products is dicult because sound scientic
evidence regarding its safety and environmental risk factors are scarce and nondenitive.94 In addition,
there are questions about whether the regulations should be enforced after research is completed but before
commercial production begins or before the research and development processes,95 whether the government
or the public should intervene in scientic research or whether the independence and freedom of science
should be protected, and whether self-regulation is adequate. According to the complexity of the science
of biotechnology and genetically modied products, there is a great possibility of the abuse of professional
power, and potential widespread and long-term harm to the environment and the well being of plant and
animal life. Due to this, I think that more regulations are necessary. But I believe we should be careful to
avoid over-control by the government, and the overestimated and abuse of social values, and the possible
counter eects of regulations such as violations of social justice and damage to economic and scientic
development.
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